References

[1] Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of Heart Failure. European Journal of Heart Failure. 2020;22(8):1342-1356. doi:10.1002/ejhf.1858

[2] Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics—2017 update: A report from the American Heart Association. Circulation. 2017;135(10). doi:10.1161/cir.0000000000000485

[3] Abraham WT, Lindenfeld JA, Reddy VY, et al. A randomized controlled trial to evaluate the safety and eﬃcacy of cardiac contractility modulation in patients with moderately reduced left ventricular ejection fraction and a narrow QRS duration: Study rationale and design. Journal of Cardiac Failure. 2015;21(1):16-23. doi:10.1016/j.cardfail.2014.09.011

[4] Kuschyk J, Falk P, Demming T, et al. Long-term clinical experience with cardiac contractility modulation therapy delivered by the optimizer smart system. European Journal of Heart Failure. 2021.doi:10.1002/ejhf.2202

[5] Abraham WT, Burkhoﬀ D, Nademanee K, et al. A randomized controlled trial to evaluate the safety and eﬃcacy of cardiac contractility modulation in patients with systolic heart failure: Rationale, design, and Baseline Patient Characteristics. American Heart Journal. 2008;156(4). doi:10.1016/j.ahj.2008.05.019